Genetic analysis of the TP53 and EGFR genes in head and neck cancers

Yasuhiro Ebihara, Miwako Iwai, Masafumi Yoshida, Mizuo Ando, Takahiro Asakage, Tatsuya Yamasoba, Yoshinori Murakami

Research output: Contribution to journalArticlepeer-review


To identify useful molecular markers for the treatment of head and neck cancers (HNCs), mutations of the TP53 and EGFR genes were analyzed in 56 HNCs, including 39 head and neck squamous cell carcinomas (HNSCCs). No EGFR mutation was observed in the fragments of exons 18-21. By contrast, 17 of 39 (44%) HNSCCs, as well as 3 of 6 cases (50%) with salivary gland carcinoma showed TP53 mutation in the fragments of exons 5-9. The incidence of nonsense mutation was 47%, which was higher than that in previous reports in other countries, suggesting the presence of etiological factors characteristic to Japanese patients. Further clinical assessment, including drug response and prognosis, is required in HNSCCs carrying the null-type mutation of TP53.

Original languageEnglish
Pages (from-to)1-6
Number of pages6
JournalJapanese Journal of Head and Neck Cancer
Issue number1
Publication statusPublished - 2011
Externally publishedYes


  • EGFR
  • Head and neck cancer
  • Nonsense mutation
  • TP53

ASJC Scopus subject areas

  • Otorhinolaryngology
  • Oncology


Dive into the research topics of 'Genetic analysis of the TP53 and EGFR genes in head and neck cancers'. Together they form a unique fingerprint.

Cite this